EAM Investors LLC Sells 27,125 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

EAM Investors LLC lowered its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 16.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 134,124 shares of the biopharmaceutical company's stock after selling 27,125 shares during the quarter. EAM Investors LLC owned about 0.11% of Catalyst Pharmaceuticals worth $2,799,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in CPRX. Steward Partners Investment Advisory LLC bought a new position in Catalyst Pharmaceuticals in the fourth quarter valued at $27,000. Farther Finance Advisors LLC boosted its position in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after purchasing an additional 1,495 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $65,000. KBC Group NV raised its stake in shares of Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after purchasing an additional 1,542 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at approximately $134,000. Institutional investors own 79.22% of the company's stock.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Gary Ingenito sold 44,904 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares of the company's stock, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.00% of the company's stock.

Analyst Ratings Changes

CPRX has been the subject of a number of recent analyst reports. Bank of America reiterated a "buy" rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Robert W. Baird lifted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Finally, HC Wainwright reissued a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Catalyst Pharmaceuticals has an average rating of "Buy" and a consensus price target of $32.29.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX traded up $0.52 during trading hours on Tuesday, hitting $22.54. 158,777 shares of the stock were exchanged, compared to its average volume of 1,107,987. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.47 and a 1-year high of $26.16. The company has a market cap of $2.75 billion, a PE ratio of 19.11, a price-to-earnings-growth ratio of 3.31 and a beta of 0.79. The company's fifty day simple moving average is $22.59 and its two-hundred day simple moving average is $22.13.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.